Canaccord Genuity reiterated a buy rating and issued a $44.00 price target on shares of Stoke Therapeutics in a report on Thursday, July 9th. On average, they anticipate Stoke Therapeutics' share price to reach $36.80 in the next twelve months. To see all exchange delays and terms of use please see disclaimer. Learn about financial terms, types of investments, trading strategies and more. STOK stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., FMR LLC, Goldman Sachs Group Inc., Artal Group S.A., SG Americas Securities LLC, Athanor Capital LP, Jane Street Group LLC, and California Public Employees Retirement System. Will Live Nation Entertainment (NYSE: LYV) Return to Pre-Pandemic Heights? Do Not Sell My Information. Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings data on Monday, August 10th. Get short term trading ideas from the MarketBeat Idea Engine. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Stoke Therapeutics trades on the NASDAQ under the ticker symbol "STOK.". Click here to tap into these high powered biotech stocks now! View analysts' price targets for Stoke Therapeutics. The Investor Relations website contains information about Stoke Therapeutics 's business for stockholders, potential investors, and financial analysts. Stoke Therapeutics employs 44 workers across the globe. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by $0.04. The official website for Stoke Therapeutics is www.stoketherapeutics.com. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA. Trump taps conservative Barrett for Supreme Court, He went from multibillionaire to relatively broke and living in a small apartment — just like he planned, A Right-Leaning Supreme Court Will Tackle Some Big Business Cases, This tax break for first-time home buyers could keep the housing market afloat, Stoke Therapeutics started at outperform with $31 stock price target at Wedbush, Stoke Therapeutics started at buy with $46 stock price target at BTIG, Stoke Therapeutics started at overweight with $34 stock price target at J.P. Morgan, Stoke Therapeutics set terms of IPO, which would value company at up to $484.3 mln, Stoke Therapeutics shares soar 46% in trading debut, Stoke Therapeutics to raise up to $107 million in IPO, H.C. Wainwright Reaffirms Their Buy Rating on Stoke Therapeutics (STOK), Stoke Therapeutics (STOK) Received its Third Buy in a Row, Stoke Therapeutics (STOK) Receives a Buy from H.C. Wainwright. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Terms of Service | Privacy Policy. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. See what's happening in the market right now with MarketBeat's real-time news feed. See what's happening in the market right now with MarketBeat's real-time news feed. Stoke Therapeutics has a market capitalization of $1.15 billion. Stoke's STK-001 shows encouraging action in preclinical study, Stoke's STK-001 preclinical data published in a science journal, After Credit Suisse and Canaccord Genuity gave Stoke Therapeutics (NASDAQ: STOK) a Buy rating last month, the company received another Buy, this time ...[...], SAM, SOGO, INTC and EHTH among midday movers, Stoke Therapeutics Announces Appointment of Garry E. Menzel, Ph.D., to its Board of Directors, Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Yahoo fait partie de Verizon Media. Privacy Notice and Fundamental company data provided by Morningstar and Zacks Investment Research. The stock has a consensus rating of Buy and an average price target of $34.83. Looking for new stock ideas? We believe Stoke’s proprietary TANGO technology platform can be used to treat a broad spectrum of genetic diseases in which the patient has one healthy copy of a gene and one mutated copy that fails to produce a protein essential to health. Vanguard Group Inc. now owns 1,278,341 shares of the company’s stock worth $30,462,000 after purchasing an additional 482,351 shares during the last quarter. By using this site you agree to the Company insiders that have bought Stoke Therapeutics stock in the last two years include Apple Tree Partners Iv, LP, and Rtw Investments, Lp.